Low molecular weight heparin use during pregnancy: Issues of safety and practicality

Obstetrical and Gynecological Survey

Volumn 54, Issue 10, 1999, Pages 649-654

  Chan, Wee Shian ^a   Ray, Joel G ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; REVIPARIN; TINZAPARIN;

DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; HUMAN; PREGNANCY DISORDER; REVIEW; THROMBOEMBOLISM;

BLOOD COAGULATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; SAFETY; THROMBOEMBOLISM;

EID: 0037712625     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199910000-00022     Document Type: Review

References (38)

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698.
2. Hirsh J, Raschke R, Warkentin TE et al. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-275S.
3. Kessler CM. Low molecular weight heparins: Practical considerations. Semin Hematol 1997;34:35-42.
4. Nurmohamed MT, ten Cate H, ten Cate JW. Low molecular weight heparin(oid)s. Drugs 1997;53:736-751.
5. Frydman A. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics, and metabolism in humans. Haemostasis 1996;26:24-38.
6. Gillis S, Shisnan A, Eldor A. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 1992;39:297-301.
7. Melisarri E, Parker CJ, Wilson NV et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992;68:652-656.
8. Manoharan A. Use of low-molecular weight heparin during pregnancy. J Clin Pathol 1994;47:94-95.
9. Ramussen C, Wadt J, Jacobsen B. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int J Gynaecol Obstet 1994;47:121-125.
10. Kraub T, Rath W, Dittmer U et al. Use of LMW heparin (Fragmin) for the prevention of thromboembolism in obstetrics. Z Geburtshilfe Perinatol 1994;198:120-125.
11. Sturridge F, Letsky EA, de Swiet M. The use of low molecular weight heparin for thromboprophylaxis. Br J Obstet Gynaecol 1994;101:69-71.
12. Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. Haemost 1994;24:55-56.
13. Boda Z, Laszlo P, Retjo L et al. Low molecular weight heparin and thromboprophylaxis in familial thrombophilia during the whole period of pregnancy [letter]. Thromb Haemost 1996;26: 128.
14. Dulitzki M, Pauzner R, Langevitz P et al. Low molecular weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87:380-383.
15. Lima F, Khamashta MA, Buchanan NMM et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131-136.
16. Hunt JB, Doughty HA, Majumbar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997;77:39-43.
17. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062-1068.
18. Schneider DM, von Tempelhoff G, Heilmann L. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin as thromboprophylaxis during pregnancy. Am J Obstet Gynecol 1997;177:1567-1568.
19. Daskalakis G, Antsaklis A, Papageorgiou I et al. Thrombosis prophylaxis after treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 1997;74:165-167.
20. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996;65:171-174.
21. Casele H, Laifer S. Prospective evaluation of bone density changes in pregnant women on low molecular weight heparin [abstract]. Am J Obstet Gynecol 1998;178:365.
22. Forestier F, Daffos F, Capell-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34:557-560.
23. Forestier F, Daffos F, Rainaut M et al. Low molecular weight heparin (CY 216) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb Haemost 1987;57:234.
24. Omri A, Dellaloye JF, Anderson H et al. Low molecular weight heparin novo (LHN-1) does not cross the placenta during the second trimester of preganncy. Thromb Haemost 1989;1:55-56.
25. Harenberg J, Schneider D, Heilmann L et al. Lack of antifactor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Thromb Haemost 1993;23:314-320.
26. Schneider DM, Heilmann L, Harenberg J. Placental passage of low molecular weight heparin. Geburtshilfe Frauenheilkd 1995;55:93-98.
27. Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annu Rev Med 1989;40:79-86.
28. Leizorovicz A, Simonneau G, Decousus H et al. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heaparin in initial treatment of deep vein thrombosis: A meta-analysis. BMJ 1994;309:299-304.
29. Lensing AWA, Prins MH, Davidson BL et al. Treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis. Arch Intern Med 1995;155:601-607.
30. Siragusa S, Cosmi B, Piovella F et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996;100:269-277.
31. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
32. Dahlman TC. Osteoporotic fractures and recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993;168:1265-1270.
33. Monreal M, Lafoz E, Olive A et al. Comparison of subcutaneous unfractionated heparin with a low molecular heparin (Frogman) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994;71:7-11.
34. Buller HR, Gent M, Gallus AS et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662.
35. Simonneau G, Sors H, Charbonnier B et al. A comparison of low-molecular-weight heparin with unfractionated heparin for active pulmonary embolism. N Engl J Med 1997;332:663-669.
36. Horlocker TT, Heit JA. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic mangement. Anesth Analg 1997;85:874-885.
37. Tryba M, Wedel DJ. Central neuraxial block and low molecular weight heparin (enoxaparine): Lessons learned from different dosage regimes in two continents. Reg Anaesth 1997;111: 100-104.
38. L'E Orme M, Lewis PJ, de Swiet M et al. May mothers given warfarin breast-feed their infants? BMJ 1977;1:1564-1565.